Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CTSH | P09668 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969953 | 1.00 | CTSK (0.36) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL970848 | 0.87 | PIK3CD (0.31) | CTSS | |
| SCHEMBL7360310 | 0.82 | CTSK (0.35) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL2176857 | 0.79 | — | — | |
| SCHEMBL7364108 | 0.78 | CTSK (0.33) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL969247 | 0.76 | CACNA2D1 (0.33) | — | |
| SCHEMBL7364034 | 0.75 | CTSS (0.30) | CTSS | |
| SCHEMBL7363475 | 0.75 | CTSS (0.30) | CTSS | |
| SCHEMBL7300069 | 0.75 | CTSK (0.33) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL1862554 | 0.75 | CTSK (0.39) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CTSK 31/4885CTSS 138/4885CTSL 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.